Literature DB >> 23412972

Medical prophylaxis: the value of an "opt in" policy.

Mark A Crowther1.   

Abstract

Medical thromboprophylaxis reduces venous thromboembolism (VTE), while causing bleeding. Routine application of pharmacological VTE prophylaxis to low risk medical patients is likely to cause net harm; as a result only moderate or high risk patients should be exposed to VTE prophylaxis. To avoid unneeded exposure to VTE prophylaxis health care providers should use an "opt-in" policy which does not default to the use of VTE prophylaxis in inappropriate patients.

Entities:  

Mesh：

Year:  2013        PMID： 23412972     DOI： 10.1007/s11239-013-0881-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  11 in total

1.  Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.

Authors:  Francesco Dentali; James D Douketis; Monica Gianni; Wendy Lim; Mark A Crowther
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

2.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Low-molecular-weight heparin and mortality in acutely ill medical patients.

Authors:  Ajay K Kakkar; Claudio Cimminiello; Samuel Z Goldhaber; Rajiv Parakh; Chen Wang; Jean-François Bergmann
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.

Authors:  Deborah Cook; Mark Crowther; Maureen Meade; Christian Rabbat; Lauren Griffith; David Schiff; William Geerts; Gordon Guyatt
Journal:  Crit Care Med       Date:  2005-07       Impact factor: 7.598

5.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

Review 6.  Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline.

Authors:  Frank A Lederle; Dylan Zylla; Roderick MacDonald; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2011-11-01       Impact factor: 25.391

7.  Electronic alerts to prevent venous thromboembolism among hospitalized patients.

Authors:  Nils Kucher; Sophia Koo; Rene Quiroz; Joshua M Cooper; Marilyn D Paterno; Boris Soukonnikov; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

9.  Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Roger Chou; Linda L Humphrey; Melissa Starkey; Paul Shekelle
Journal:  Ann Intern Med       Date:  2011-11-01       Impact factor: 25.391

10.  Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.

Authors:  Deborah Cook; James Douketis; Maureen Meade; Gordon Guyatt; Nicole Zytaruk; John Granton; Yoanna Skrobik; Martin Albert; Robert Fowler; Paul Hebert; Guiseppe Pagliarello; Jan Friedrich; Andreas Freitag; Tim Karachi; Christian Rabbat; Diane Heels-Ansdell; William Geerts; Mark Crowther
Journal:  Crit Care       Date:  2008-03-03       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.